REGISTERED NUMBER: |
Hospital Innovation Holdings Limited |
Financial Statements for the Period 6 April 2023 to 30 June 2024 |
REGISTERED NUMBER: |
Hospital Innovation Holdings Limited |
Financial Statements for the Period 6 April 2023 to 30 June 2024 |
Hospital Innovation Holdings Limited (Registered number: 14784969) |
Contents of the Financial Statements |
for the Period 6 April 2023 to 30 June 2024 |
Page |
Company Information | 1 |
Balance Sheet | 2 |
Notes to the Financial Statements | 3 |
Hospital Innovation Holdings Limited |
Company Information |
for the Period 6 April 2023 to 30 June 2024 |
Directors: |
Registered office: |
Registered number: |
Auditors: |
7 Neptune Court |
Vanguard Way |
Cardiff |
CF24 5PJ |
Hospital Innovation Holdings Limited (Registered number: 14784969) |
Balance Sheet |
30 June 2024 |
Notes | £ |
Fixed assets |
Tangible assets | 4 |
Investments | 5 |
Total assets less current liabilities |
Capital and reserves |
Called up share capital | 6 |
Capital redemption reserve | ( |
) |
Retained earnings |
The financial statements were approved by the Board of Directors and authorised for issue on |
Hospital Innovation Holdings Limited (Registered number: 14784969) |
Notes to the Financial Statements |
for the Period 6 April 2023 to 30 June 2024 |
1. | Statutory information |
Hospital Innovation Holdings Limited is a |
2. | Accounting policies |
Basis of preparing the financial statements |
Preparation of consolidated financial statements |
The financial statements contain information about Hospital Innovation Holdings Limited as an individual company and do not contain consolidated financial information as the parent of a group. The company is exempt under Section 400 of the Companies Act 2006 from the requirements to prepare consolidated financial statements as it and its subsidiary undertaking are included by full consolidation in the consolidated financial statements of its parent, MedScience Group Limited, . |
Tangible fixed assets |
Investments in subsidiaries |
Investments in subsidiary undertakings are recognised at cost. |
Taxation |
Taxation for the period comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. |
Current or deferred taxation assets and liabilities are not discounted. |
Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date. |
Deferred tax |
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date. |
Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the period end and that are expected to apply to the reversal of the timing difference. |
Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. |
3. | Employees and directors |
The average number of employees during the period was NIL. |
Hospital Innovation Holdings Limited (Registered number: 14784969) |
Notes to the Financial Statements - continued |
for the Period 6 April 2023 to 30 June 2024 |
4. | Tangible fixed assets |
Freehold |
property |
£ |
Cost |
Additions |
Disposals | ( |
) |
At 30 June 2024 |
Net book value |
At 30 June 2024 |
During the period, the company received a dividend in specie from its subsidiary of a property at fair value. The property was subsequently transferred out under a restructure to a non Group company. |
5. | Fixed asset investments |
Shares in |
group |
undertaking |
£ |
Cost |
Additions |
Disposals | ( |
) |
At 30 June 2024 |
Net book value |
At 30 June 2024 |
Hospital Innovations Holdings has a 100% investment in Hospital Innovations Limited to the value of £100. |
During the period, the company received a dividend in specie from its subsidiary of an investment at fair value. The investment was subsequently transferred out under a restructure to a non Group company. |
6. | Called up share capital |
On incorporation, the company issued 100 ordinary shares of £1 each to Mr W P Davies. |
On 9 June 2023 a further 100 ordinary shares of £1 each were allotted to Mr Davies, with the 200 shares reclassified into 100 I shares and 100 T shares. |
On 28 June 2023, by written resolution and as part of a restructuring exercise, the issued share capital of the company was reduced from £200 to £100 by cancelling and extinguishing 100 issued I ordinary shares of £1 each in the company, leaving the 100 T ordinary shares. On this date, the remaining T shares transferred ownership from Mr W P Davies to Medscience Distribution Ltd. |
7. | Disclosure under Section 444(5B) of the Companies Act 2006 |
The Report of the Auditors was unqualified. |
for and on behalf of |
8. | Ultimate controlling party |
As at 30th June 2024, the immediate parent company is Medscience Disbtribution Ltd (02491098), the ultimate parent company is MedScience Group Limited (IE420569). The registered office for the immediate parent company is available on Companies House, whilst the group parent registered office is Unit 3, Clonmore Business Park, Mullingar, Co. Westmeath, N91 DK59. |